钠-葡萄糖协同转运蛋白2抑制剂治疗阻塞性睡眠呼吸暂停的研究进展  

Research advances of sodium-glucose cotransporter 2 inhibitors for the treatment of obstructive sleep apnea

作　　者：高璐阳 黄志华 罗勤[1] 赵智慧[1] 赵青[1] 柳志红[1] GAO Luyang;HUANG Zhihua;LUO Qin;ZHAO Zhihui;ZHAO Qing;LIU Zhihong(Center for Pulmonary Vascular Disease,Fuwai Hospital of Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,100037)

机构地区：[1]中国医学科学院北京协和医学院阜外医院肺血管病中心,北京100037

出　　处：《实用临床医药杂志》2023年第7期133-137,共5页Journal of Clinical Medicine in Practice

基　　金：中央高水平医院临床科研业务费资助项目(2022-GSP-GG-35);首都卫生发展科研专项项目(2020-SHF03)。

摘　　要：阻塞性睡眠呼吸暂停(OSA)是一种常见的睡眠呼吸障碍性疾病,其特征是睡眠期间反复出现上气道阻塞,导致间歇性低氧和睡眠片段化。持续气道正压通气是OSA的一线治疗方法,但因依从性不佳等因素尚未得到广泛应用。新型降糖药格列净类药物是一种钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2i),已应用于糖尿病、心力衰竭与慢性肾脏病等疾病的临床治疗中。近年来,有研究显示,SGLT-2i可以使OSA患者获益。作者对格列净类药物用于治疗OSA的研究进展进行综述。Obstructive Sleep apnea(OSA)is a common sleep-breathing disorder characterized by recurrent upper airway obstruction during sleep,resulting in intermittent hypoxia and sleep fragmentation.Continuous positive airway pressure is the first-line treatment for OSA,but it has not been widely used due to poor compliance and other factors.The new hypoglycemic drug gliflozin is a sodium-glucose cotransporter 2 inhibitor,which has been used in the clinical treatment of diabetes,heart failure,chronic kidney disease and other diseases.In recent years,studies have suggested that SGLT-2i can benefit OSA patients.This author reviewed the research progress of gliflozin in the treatment of OSA.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 阻塞性睡眠呼吸暂停 2型糖尿病 心力衰竭 慢性肾脏病 胰岛素抵抗 

分 类 号：R766[医药卫生—耳鼻咽喉科] R587.1[医药卫生—临床医学]